Phospholemman: its role in normal cardiac physiology and potential as a drugable target in disease

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 160-166

  Shattock, Michael J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PHOSPHOLAMBAN; PHOSPHOLEMMAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SARCOPLASMIC RETICULUM; SEPSIS;

ANIMALS; CARDIOMEGALY; DRUG DELIVERY SYSTEMS; HEART; HEART FAILURE; HUMANS; MEMBRANE PROTEINS; NITRIC OXIDE; PHOSPHOPROTEINS; RECEPTORS, ADRENERGIC, BETA; REPERFUSION INJURY; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 62249105157     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.12.015     Document Type: Review

References (51)

1. Mullins L.J. Ion transport in heart (1981), Raven Press, New York
2. Molitoris B.A., and Kinne R. Ischemia induces surface membrane dysfunction: mechanism of altered Na+-dependent glucose transport. J Clin Invest 80 (1987) 647-654
3. Fuller W., Eaton P., Bell J.R., and Shattock M.J. Ischemia-induced phosphorylation of phospholemman directly activates rat cardiac Na/K-ATPase. FASEB J 18 (2004) 197-199. This study describes for the first time the phospho-regulation of the cardiac Na/K ATPase by the phosphorylation of phospholemman. In this study, PLM is shown to physically associate with the cardiac Na/K ATPase and PLM phosphorylation mediates stimulation of Na/K pump activity. Cross-linking studies show that the association between the Na/K ATPase α-subunit and PLM is altered by phosphorylation.
4. Silverman B.Z., Fuller W., Eaton P., Deng J., Moorman J.R., Cheung J.Y., James A.F., and Shattock M.J. Serine 68 phosphorylation of phospholemman: acute isoform-specific activation of cardiac Na/K ATPase. Cardiovasc Res 65 (2005) 93-103
5. Fuller W., and Shattock M.J. Phospholemman (FXYD1) is a substrate for multiple protein kinases in vitro. Biophys J 88 (2005) 2946-Pos
6. Berry R.G., Fuller W., Tucker A.L., and Shattock M.J. Na/K ATPase pump current is increased in ventricular myocytes isolated from phospholemman knockout mice. J Physiol 565P (2005) C171
7. Pavlovic D., Fuller W., and Shattock M.J. The intracellular region of FXYD1 is sufficient to regulate cardiac Na/K ATPase. FASEB J 21 (2007) 1539-1546
8. Berry R.G., Fuller W., and Shattock M.J. Regulation of cardiac Na/K ATPAse by FXYD1 (phospholemman). J Mol Cell Cardiol 40 (2006) 997A
9. Han F., Bossuyt J., Despa S., Tucker A.L., and Bers D.M. Phospholemman phosphorylation mediates the protein kinase C-dependent effects on Na+/K+ pump function in cardiac myocytes. Circ Res 99 (2006) 1376-1383
10. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., Doetschman T., and Kranias E.G. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75 (1994) 401-409
11. Despa S., Tucker A.L., and Bers D.M. Phospholemman-mediated activation of Na/K-ATPase limits [Na]i and inotropic state during beta-adrenergic stimulation in mouse ventricular myocytes. Circulation 117 (2008) 1849-1855. This reference shows that the rise in intracellular Na induced by a pacing rate increase can be almost completely abrogated by β-adrenoreptor stimulation and this effect is absent in PLM KO mice. Thus demonstrating the physiological role of PLM-to keep intracellular Na low when heart rate increases.
12. Zhao W., Uehara Y., Chu G., Song Q., Qian J., Young K., and Kranias E.G. Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. J Mol Cell Cardiol 37 (2004) 607-612
13. Sears C.E., Ashley E.A., and Casadei B. Nitric oxide control of cardiac function: is neuronal nitric oxide synthase a key component?. Philos Trans R Soc Lond B Biol Sci 359 (2004) 1021-1044
14. Khan S.A., Skaf M.W., Harrison R.W., Lee K., Minhas K.M., Kumar A., Fradley M., Shoukas A.A., Berkowitz D.E., and Hare J.M. Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res 92 (2003) 1322-1329
15. Valverde C.A., Mundina-Weilenmann C., Said M., Ferrero P., Vittone L., Salas M., Palomeque J., Petroff M.V., and Mattiazzi A. Frequency-dependent acceleration of relaxation in mammalian heart: a property not relying on phospholamban and SERCA2a phosphorylation. J Physiol 562 (2005) 801-813
16. William M., Vien J., Hamilton E., Garcia A., Bundgaard H., Clarke R.J., and Rasmussen H.H. The nitric oxide donor sodium nitroprusside stimulates the Na+-K+ pump in isolated rabbit cardiac myocytes. J Physiol 565 (2005) 815-825
17. Bundgaard H., Garcia A., Hamilton E.J., White C.N., and Rasmussen H.H. β3-receptors mediate adrenergic stimulation of the sarcolemmal Na-K pump. Biophys J 90 (2006) 556A
18. Murphy K.T., Bundgaard H., and Clausen T. Beta(3)-adrenoceptor agonist stimulation of the Na(+), K(+)-pump in rat skeletal muscle is mediated by beta(2)- rather than beta(3)-adrenoceptors. Br J Pharmacol 149 (2006) 635-646
19. Tani M., and Neely J.R. Role of intracellular Na in Ca overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Circ Res 65 (1989) 1045-1056. This is a classic paper showing that intracellular Na overload is a key determinant of cell injury in ischaemia and reperfusion.
20. •], highlights the importance of Na overload as a determinant of tissue injury in ischaemia and reperfusion. This paper makes the additional observation that Na overload is a key determinant of electrical dysfunction.
21. Pogwizd S.M., Sipido K.R., Verdonck F., and Bers D.M. Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57 (2003) 887-896
22. + exchange. Am J Physiol 265 (1993) H2017-H2026
23. Bernard M., and Ingwall J. Intracellular sodium concentration and accumulation during ischemia in isolated perfused rat and guinea pig hearts. J Mol Cell Cardiol 23 (1991) S8
24. 23TA NMR study. J Mol Cell Cardiol 23 (1991) 297-307
25. 23Na NMR spectroscopy (still the 'gold standard' technique for measuring intracellular Na in intact beating hearts) to measure intracellular Na changes during real (not simulated) ischaemia and reperfusion. This reference (at hypothermic temperatures) and reference [24] (at normothermic temperatures) show that ischaemia causes intracellular Na to rise immediately increasing steadily to 25-30 mM. Importantly, neither of the studies cited here (nor later studies from the van Echteld group with better (<5 s) temporal resolution) could show evidence for the previously hypothesised increase in intracellular Na in the early seconds of reperfusion.
26. Hasenfuss G., and Maier L.S. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 97 (2008) 222-226
27. Allen D.G., and Orchard C.H. Myocardial contractile function during ischemia and hypoxia. Circ Res 60 (1987) 153-168
28. •]).
29. Verdonck F., Volders P.G., Vos M.A., and Sipido K.R. Intracellular Na+ and altered Na+ transport mechanisms in cardiac hypertrophy and failure. J Mol Cell Cardiol 35 (2003) 5-25
30. Pieske B., Maier L.S., Piacentino III V., Weisser J., Hasenfuss G., and Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 106 (2002) 447-453. This paper is one of many studies demonstrating that intracellular Na is high in the failing myocardium. In this study, they show that this high Na, at low rates of stimulation, may maintain contractility. However, since this study uses electrical pacing, rather than β-receptor stimulation, it does not provide insight into the role of PLM in regulating Na at physiologically induced (i.e. by catecholamines) high heart rates.
31. Despa S., Islam M.A., Weber C.R., Pogwizd S.M., and Bers D.M. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 105 (2002) 2543-2548
32. Verdonck F., Volders P.G., Vos M.A., and Sipido K.R. Increased Na+ concentration and altered Na/K pump activity in hypertrophied canine ventricular cells. Cardiovasc Res 57 (2003) 1035-1043
33. Shattock M.J., and Bers D.M. Rat vs. rabbit ventricle: Ca flux and intracellular Na assessed by ion-selective microelectrodes. Am J Physiol 256 (1989) C813-C822
34. Kennington E., Fuller W., and Shattock M.J. Characterisation of the Langendorff-perfused phospholemman knockout mouse heart: effects of calcium concentration and pacing rate on contractility. J Mol Cell Cardiol 40 (2006) 209
35. Bristow M.R. Why does the myocardium fail? Insights from basic science. Lancet 352 Suppl. 1 (1998) SI8-14
36. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., Billingham M.E., Harrison D.C., and Stinson E.B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
37. Neumann J., Eschenhagen T., Jones L.R., Linck B., Schmitz W., Scholz H., and Zimmermann N. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol 29 (1997) 265-272
38. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., Weiser D., Hahn H., Carr A.N., Syed F., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96 (2005) 756-766
39. Parrillo J.E. Pathogenetic mechanisms of septic shock. N Engl J Med 328 (1993) 1471-1477
40. Grocott-Mason R.M., and Shah A.M. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med 24 (1998) 286-295
41. Hall A.R., McLatchie L.M., Fuller W., and Shattock M.J. Nitric oxide-induced stimulation of the cardiac Na/K ATPase requires phospholemman. J Mol Cell Cardiol 42 6 Suppl. 1 (2007) S54. Although only in abstract form, this is the first report implicating PLM in the stimulation of the Na/K ATPase by nitric oxide.
42. Cornelius F., and Mahmmoud Y.A. Functional modulation of the sodium pump: the regulatory proteins 'Fixit'. News Physiol Sci 18 (2003) 119-124
43. Chen S.J., Chen K.H., Webb R.C., Yen M.H., and Wu C.C. Abnormal activation of Na+-K+ pump in aortas from rats with endotoxaemia. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 57-62
44. Gupta S., Moreland R.B., Munarriz R., Daley J., Goldstein I., and Saenz de Tejada I. Possible role of Na(+)-K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide. Br J Pharmacol 116 (1995) 2201-2206
45. Hale S.L., and Kloner R.A. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J Cardiovasc Pharmacol Ther 13 (2008) 226-232
46. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., Murphy S.A., Budaj A., Varshavsky S., Wolff A.A., Skene A., McCabe C.H., and Braunwald E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297 (2007) 1775-1783. This is the first report of a clinical trial investigating the effects of a drug suggested to block Na influx into the myocardium in angina. The study shows evidence for protection against arrhythmias.
47. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99 (1999) 641-648
48. Rasmussen H.H., and Figtree G. Don't flog the heart!-development of specific drug therapies for heart failure. Crit Care Resusc 9 (2007) 364-369
49. Franzin C.M., Gong X.M., Thai K., Yu J., and Marassi F.M. NMR of membrane proteins in micelles and bilayers: the FXYD family proteins. Methods 41 (2007) 398-408
50. Teriete P., Franzin C.M., Choi J., and Marassi F.M. Structure of the Na, K-ATPase regulatory protein FXYD1 in micelles. Biochemistry 46 (2007) 6774-6783
51. Silverman B.Z. Regulation of the Na/K pump in guinea pig cardiac ventricular myocytes (2001), King's College London, University of London, London